



RNAi THERAPEUTICS AND THE ELEVATE REGISTRY:


Shaping the Future of AHP Patient Care

Dear ICPP 2022 registrant,

In the last 20 years, RNAi therapeutics have evolved from bench to bedside and are now a treatment option for patients with rare and prevalent diseases.¹

Join us for an Alnylam Pharmaceuticals-sponsored symposium on **RNAi Therapeutics and the ELEVATE Registry: Shaping the Future of AHP Patient Care** at ICPP 2022, on 5th September 2022.

Hear from Ivan Zlatev, PhD, Director of Research, and Mary-Jean Fanelli, MD, Executive Director, Global Medical Affairs, from Alnylam Pharmaceuticals as they share their insights into the development of RNAi therapeutics and ELEVATE, a registry of patients with AHP.²



Ivan Zlatev PhD
Director of Research,
Alnylam Pharmaceuticals



Mary-Jean Fanelli MD
Executive Director, Global Medical
Affairs, Alnylam Pharmaceuticals

Join us for an Alnylam Pharmaceuticals-sponsored symposium

RNAi THERAPEUTICS AND THE ELEVATE REGISTRY: Shaping the Future of AHP Patient Care

5th September 2022, 07:30–08:30 (EET)

Grand Hotel Millennium, Sofia, Bulgaria

Symposium Objectives

To enable attendees to:

- Understand the mechanism of action of RNAi therapeutics
- Recognise the potential applications of RNAi technology to treat rare and prevalent diseases
- Understand the importance of gathering long-term, real-world evidence on the clinical management of patients with AHP
- Appreciate the role that real-world evidence generation has on the future of AHP care

Agenda

Duration	Titles	Speaker
7:30–7:35	Welcome and Introduction	
7:35–7:55	The Journey to Targeted RNAi Therapeutics <i>Plenary session</i> • Development and mechanism of action of RNAi therapeutics • Brief overview of the application of RNAi therapeutics	Ivan Zlatev <i>Director, Research</i>
7:55–8:15	Looking Ahead: The ELEVATE Registry and the Future of Patient Care <i>Plenary session</i> • Study design and objectives of the ELEVATE registry • Aims of the ELEVATE registry and the burden of living with AHP	Mary-Jean Fanelli <i>Executive Director, Global Medical Affairs</i>
8:15–8:30	Q&A	Ivan Zlatev & Mary-Jean Fanelli
8:30	Meeting Close	

AHP, acute hepatic porphyria; EET, Eastern European Time; ICPP, International Conference on Porphyrins and Porphyrins; RNAi, ribonucleic acid interference.

This symposium will contain information on products developed and marketed by Alnylam Pharmaceuticals.

This symposium is organised and funded by Alnylam Pharmaceuticals, for healthcare professionals only. This symposium is not a Continuing Education (CE) activity.

References:

1. Fire A et al. *Nature* 1998;391:806–811; 2. ClinicalTrials.gov. Available at: <https://clinicaltrials.gov/ct2/show/NCT04883905> (Accessed August 2022).